SID 0014 Entellus Medical
from Stocks-in-Depth
Entellus Medical came public in January 2015 under the premise that it was the leader in office-based balloon sinus dilation, which was a small but increasingly preferred niche compares to FESS operations performed in hospitals. The investment research discussed in this podcast examines whether changes in medicare reimbursement may have been a setback that favored hybrid-FESS procedures, and how steroid implants may have temporarily affected what seemed to be an inevitable shift to treating chronic sinusitis in a dentist-like procedure. We also discuss complications that arise, and the suitability of dealing with these outside of the operating room.
Embed this episode
No transcript yet.